As we mark World Cancer Day 2026 today, groundbreaking research published in JAMA Otolaryngology-Head & Neck Surgery reveals an alarming connection that challenges widespread assumptions about cannabis safety. The study shows that adults with cannabis use disorder face dramatically elevated risks of developing various forms of head and neck malignancies, with rates 3.5 to 5 times higher than non-users.

This finding adds cannabis to the established list of modifiable risk factors for these devastating diseases, joining tobacco use, excessive alcohol consumption, and human papillomavirus exposure. The evidence demands urgent attention as cannabis becomes increasingly normalised and legally accessible across numerous jurisdictions.

The Landmark Study on Cannabis Use and Neck Cancer

Researchers from the University of Southern California Keck School of Medicine analysed an unprecedented dataset spanning two decades to examine this relationship. The multicentre cohort study examined clinical records from 64 healthcare organisations across the United States, encompassing more than 4 million patient records through April 2024.

The cannabis-related disorder cohort included 116,076 individuals with a mean age of 46.4 years. These patients were matched with controls based on demographic characteristics, alcohol-related disorders, and tobacco use. After propensity score matching created two groups of 115,865 individuals each, the results proved stark. Patients with cannabis-related disorder demonstrated a significantly higher risk of any form of head and neck malignancy, with a relative risk of 3.49 compared to those without the disorder. The findings remained consistent across both younger and older age groups, suggesting this risk transcends generational boundaries.

Site-Specific Risks: Where the Connection Proves Strongest

The research revealed particularly concerning patterns when examining specific anatomical sites. Those with cannabis-related disorder faced a relative risk of 2.51 for oral cavity malignancies affecting the mouth and surrounding structures. The association proved even stronger for oropharyngeal tumours, which develop in the soft palate, tonsils, and back of the throat, with a relative risk of 4.90.

Most alarmingly, laryngeal malignancies affecting the voice box showed a relative risk of 8.39. This eight-fold increase represents one of the strongest associations identified in cancer epidemiology research. Dr Niels Kokot, senior author of the study and head and neck surgeon at Keck Medicine, emphasised the importance of these findings. “The detection of this risk factor is important because head and neck cancer may be preventable once people know which behaviours increase their risk,” he explained.

Understanding Head and Neck Malignancies

Head and neck cancer represents the sixth most common cancer worldwide. In the United States, these malignancies account for 4% of all cancer diagnoses, with more than 71,000 new cases and over 16,000 deaths expected annually. Traditionally, these conditions predominantly affected people over 50 years of age. However, the increasing incidence of HPV-related cases has shifted this pattern, with more younger adults receiving diagnoses.

The malignancies typically present with persistent sore throat, difficulty swallowing, unexplained lumps in the neck, persistent hoarseness, and chronic ear pain. Early detection significantly improves treatment outcomes, making awareness of risk factors crucial for prevention.

Why Smoking Cannabis May Cause These Malignancies

Researchers hypothesise that the primary mechanism involves the damaging effects of smoke inhalation. Cannabis consumption predominantly occurs through smoking, and this appears central to understanding the elevated risks.

Dr Kokot explains the characteristics that make cannabis smoke particularly harmful. “Cannabis smoking is typically unfiltered and involves deeper inhalation compared to tobacco. Additionally, cannabis burns at a higher temperature than tobacco, increasing the risk of cancer-causing inflammation.” The deeper inhalation patterns mean carcinogenic compounds spend more time in contact with delicate throat and mouth tissues. The higher burning temperature generates additional toxic byproducts. Combined with the unfiltered nature of most consumption, these factors create optimal conditions for cellular damage.

Cannabis smoke contains many of the same toxic chemicals found in tobacco smoke, including polycyclic aromatic hydrocarbons and volatile aldehydes. When any plant material burns, it produces thousands of chemical compounds, many of which prove carcinogenic. The combustion process generates reactive oxygen species that damage cellular DNA, whilst the smoke also contains carbon monoxide, which reduces oxygen delivery to tissues.

Research suggests the practice of holding cannabis smoke in the lungs for extended periods may intensify risks. This common behaviour amongst users seeking to maximise psychoactive effects increases exposure time to carcinogenic compounds.

Cannabis Use Disorder: Defining the Risk Population

The study focused specifically on individuals diagnosed with cannabis use disorder, a clinical condition defined by excessive consumption accompanied by psychosocial symptoms and functional impairment. According to the US Centers for Disease Control and Prevention, diagnosis requires two or more symptoms including craving cannabis, developing tolerance to its effects, using more than intended, continuing use despite life problems, using in high-risk situations, experiencing withdrawal symptoms, and inability to quit despite attempts.

Individuals with this disorder typically consume cannabis daily, often for years, placing them at elevated risk. However, the study’s limitations must be acknowledged. Hospital health records contain diagnoses but lack specific information about consumption frequency, dose, potency, or route of administration.

Dr John B. Sunwoo, director of Head and Neck Cancer Research at Stanford Medicine, notes an important caveat. “The researchers did not have information about tobacco and alcohol dosages, so we do not know if the cannabis group smoked more.” Whilst researchers attempted to control for tobacco and alcohol use through matching, differences in dosage may remain between groups.

Clinical Implications: Addressing the Risk

The American Head & Neck Society has positioned cannabis alongside tobacco and electronic cigarettes in its guidance on substance-related malignancy risks. The organisation encourages physicians to discuss cannabis consumption openly with patients as part of routine screening.

Dr Wayne Mydlarz from the American Head & Neck Society urges medical professionals “not to shy away from” talking to patients about these risks along with other high-risk behaviours. “Make this part of routine conversation and screening,” he advises. Healthcare providers face challenges discussing cannabis consumption, particularly in regions where it enjoys legal status or widespread social acceptance. However, the evidence increasingly supports frank conversations about potential harms. Patients deserve accurate information to make informed choices about their health.

The Broader Context of Cannabis and Health

The connection between cannabis use and neck cancer exists within a larger discussion about health effects. Whilst some research explores potential therapeutic applications of cannabinoids for specific medical conditions, the risks associated with smoking remain distinct from potential benefits of pharmaceutical-grade cannabinoid preparations.

The increasing potency of modern cannabis products raises additional concerns. Today’s cannabis contains significantly higher THC concentrations than products available decades ago. Whether higher potency correlates with increased malignancy risk remains an open question requiring investigation.

“Cannabinoids are powerful drugs that exert their effects at concentrations found with recreational use,” notes Dr Joseph Califano, who co-authored an editorial accompanying the study. “We know that because you get high.” Users typically expose themselves to complex mixtures of compounds, many with unknown health implications.

Future Research Directions

Several critical research questions demand attention. Investigators must examine whether specific consumption methods carry different risks. Do edibles, which avoid smoke exposure entirely, present the same dangers? Does vaporising, which heats cannabis without combustion, reduce carcinogenic exposure?

Researchers also need to establish clearer dose-response relationships. Does occasional use carry measurable risk, or does danger primarily affect daily users? Can people who quit reduce their risk over time? Mechanistic studies should identify whether cannabinoids themselves carry carcinogenic properties, or if harm stems primarily from combustion products.

Additionally, interaction effects require investigation to understand how cannabis consumption combines with other risk factors such as tobacco, alcohol, and HPV infection. Dr Kokot acknowledges the preliminary nature of the findings. “I would consider this a starting point to truly define what the risk is of developing head and neck cancer from cannabis use. It creates an association, but we definitely have more work to do in terms of truly defining what those risk levels are.”

World Cancer Day 2026: A Call for Awareness

Today,World Cancer Day 2026 provides an ideal opportunity to address growing concerns revealed by this research. As legalisation expands and social acceptance increases, many people perceive cannabis as harmless. This study challenges such assumptions with robust epidemiological evidence.

The investigation represents the first and largest demonstrating this association. Whilst it establishes correlation rather than definitive causation, the strength and consistency of the findings across multiple anatomical sites warrant serious attention.

For individuals with cannabis use disorder, the message proves urgent. Seeking support to reduce or eliminate consumption could significantly lower risk. Healthcare providers must include discussion of cannabis consumption in routine screening and risk assessment. Policymakers and educators face the challenge of balancing individual liberty with public health protection through evidence-based policies and comprehensive education.

Conclusion: The Evidence Demands Action

On World Cancer Day 2026, we must acknowledge compelling new evidence about cannabis use and neck cancer. The landmark study from USC Keck School of Medicine demonstrates that adults with cannabis use disorder face substantially elevated risks of developing oral, oropharyngeal, and laryngeal malignancies, with some risks exceeding eight-fold increases.

These findings challenge prevailing assumptions about cannabis safety and highlight the need for honest, evidence-based conversations. Head and neck malignancies cause significant morbidity and mortality, but they are often preventable when risk factors are identified and addressed.

The research provides robust evidence that heavy, long-term consumption significantly increases risk through mechanisms likely related to smoke inhalation. As legalisation expands and social acceptance grows, public health messaging must evolve to reflect emerging evidence.

Prevention requires addressing cannabis consumption directly, particularly amongst younger populations who may develop long-term patterns. Those currently using cannabis regularly should understand their elevated risk and consider cessation or harm reduction strategies.

World Cancer Day 2026 offers an opportunity to begin these difficult but necessary conversations, grounded in scientific evidence and motivated by genuine concern for health and wellbeing. The path forward demands honest acknowledgement that cannabis, whilst different from tobacco in many respects, shares its capacity to cause serious harm through smoke-related damage to delicate tissues.

For more information about cancer prevention and World Cancer Day initiatives, visit www.worldcancerday.org